1. Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma.
- Author
-
Terpos, Evangelos, Ramasamy, Karthik, Maouche, Nadjoua, Minarik, Jiri, Ntanasis-Stathopoulos, Ioannis, Katodritou, Eirini, Jenner, Matthew W., Plonkova, Hana, Gavriatopoulou, Maria, Vallance, Grant D., Pika, Tomas, Kotsopoulou, Maria, Kothari, Jaimal, Jelinek, Tomas, Kastritis, Efstathios, Aitchison, Robin, Dimopoulos, Meletios A., Zomas, Athanasios, and Hajek, Roman
- Subjects
- *
MULTIPLE myeloma , *PROGRESSION-free survival , *PERIPHERAL neuropathy , *DISEASE progression , *THALIDOMIDE - Abstract
Real-world data on regimens for relapsed/refractory multiple myeloma (RRMM) represent an important component of therapeutic decision-making. This multi-centric, retrospective, observational study conducted by the treating physicians evaluated the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in 155 patients who received ixazomib via early access programs in Greece, the UK, and the Czech Republic. Median age was 68 years; 17% had an Eastern Cooperative Oncology Group performance status ≥ 2; median number of prior therapies was 1 (range 1–7); 91%, 47%, and 17% had received prior bortezomib, thalidomide, and lenalidomide, respectively. Median duration of exposure to ixazomib was 9.6 months. Overall response rate was 74%, including 35% very good partial response or better (16% complete response). Median progression-free survival (PFS) was 27.6 months (27.6 and 19.9 months in patients with 1 or > 1 prior lines, respectively). IRd treatment for ≥ 6 months was associated with longer PFS (hazard ratio 0.06). Fourteen patients (9%) discontinued IRd due to adverse events/toxicity in the absence of disease progression. Peripheral neuropathy was reported in 35% of patients (3% grades 3–4). These findings support the results of the phase III TOURMALINE-MM1 trial in a broader real-world RRMM population. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF